MA45277A - Promédicaments de pth - Google Patents

Promédicaments de pth

Info

Publication number
MA45277A
MA45277A MA045277A MA45277A MA45277A MA 45277 A MA45277 A MA 45277A MA 045277 A MA045277 A MA 045277A MA 45277 A MA45277 A MA 45277A MA 45277 A MA45277 A MA 45277A
Authority
MA
Morocco
Prior art keywords
pth
medicines
Prior art date
Application number
MA045277A
Other languages
English (en)
Inventor
Felix Cleemann
Mathias Krusch
Guillaume Maitro
Kennett Sprogøe
Thomas Wegge
Joachim Zettler
Original Assignee
Ascendis Pharma Bone Diseases As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases As filed Critical Ascendis Pharma Bone Diseases As
Publication of MA45277A publication Critical patent/MA45277A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Marine Sciences & Fisheries (AREA)
MA045277A 2016-03-01 2017-02-28 Promédicaments de pth MA45277A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16158048 2016-03-01
EP16179294 2016-07-13
EP16191484 2016-09-29
EP17155839 2017-02-13

Publications (1)

Publication Number Publication Date
MA45277A true MA45277A (fr) 2019-01-09

Family

ID=58185540

Family Applications (2)

Application Number Title Priority Date Filing Date
MA045277A MA45277A (fr) 2016-03-01 2017-02-28 Promédicaments de pth
MA45809A MA45809B1 (fr) 2016-03-01 2017-02-28 Promédicaments de pth

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA45809A MA45809B1 (fr) 2016-03-01 2017-02-28 Promédicaments de pth

Country Status (30)

Country Link
US (7) US20200276276A1 (fr)
EP (2) EP4470613A3 (fr)
JP (3) JP7059195B2 (fr)
KR (4) KR102786270B1 (fr)
CN (2) CN115025239B (fr)
AU (5) AU2017227962C1 (fr)
BR (1) BR112018017091A2 (fr)
CA (2) CA3249706A1 (fr)
DK (1) DK3423103T3 (fr)
ES (1) ES2993932T3 (fr)
FI (2) FI3423103T3 (fr)
FR (1) FR24C1045I2 (fr)
HR (1) HRP20241591T1 (fr)
HU (2) HUE069445T2 (fr)
IL (3) IL317744A (fr)
LT (2) LT3423103T (fr)
MA (2) MA45277A (fr)
MX (2) MX2018009938A (fr)
MY (2) MY208384A (fr)
NL (1) NL301298I2 (fr)
NO (1) NO2025005I1 (fr)
NZ (1) NZ745318A (fr)
PL (1) PL3423103T3 (fr)
RS (1) RS66250B1 (fr)
RU (1) RU2747316C2 (fr)
SG (1) SG11201806092TA (fr)
SI (1) SI3423103T1 (fr)
SM (1) SMT202400423T1 (fr)
WO (1) WO2017148883A1 (fr)
ZA (1) ZA201805705B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065052A1 (fr) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Conjugués insuline vitamine d
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
SMT202400423T1 (it) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Profarmaci di pth
HUE063235T2 (hu) 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
NZ751746A (en) 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
SMT202300124T1 (it) 2016-09-29 2023-05-12 Ascendis Pharma Bone Diseases As Composti pth con bassi rapporti picco/valle
HUE070273T2 (hu) * 2016-09-29 2025-05-28 Ascendis Pharma Bone Diseases As Szabályozott hatóanyag-leadású PTH vegyületek
WO2019178462A1 (fr) * 2018-03-16 2019-09-19 The General Hospital Corporation Conjugués polypeptes-hormone parathyroïde et leurs procédés d'utilisation
BR112020019639A2 (pt) * 2018-03-28 2021-01-05 Ascendis Pharma Oncology Division A/S Conjugados de il-2
SMT202500272T1 (it) * 2018-05-18 2025-09-12 Ascendis Pharma Bone Diseases As Dose iniziale di coniugati di pth
US11634468B2 (en) 2019-01-29 2023-04-25 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
WO2020165087A1 (fr) 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Formulations pharmaceutiques liquides de conjugués pth
EP4090357A1 (fr) * 2020-01-13 2022-11-23 Ascendis Pharma Bone Diseases A/S Traitement de l'hypoparathyroïdisme
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
TWI888383B (zh) * 2020-06-19 2025-07-01 丹麥商阿森迪斯藥物骨疾病股份有限公司 Ｐｔｈ綴合物的液體藥物製劑
WO2021263040A1 (fr) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Formulations de pepticorps stables
EP4192508A1 (fr) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugués comprenant des lieurs réversibles et leurs utilisations
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー／エス ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
AU2024337275A1 (en) 2023-09-04 2026-02-19 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
CN118638210B (zh) * 2024-08-14 2024-11-15 南方医科大学第三附属医院（广东省骨科研究院） 长效pth类似物的制备方法及应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050148763A1 (en) * 2002-02-01 2005-07-07 Chugai Seiyaku Kabushiki Kaisha Peg-binding pth or peg-binding pth derivative
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2843439A1 (fr) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Medicaments pegyles reversibles
JP4133570B2 (ja) * 2003-05-15 2008-08-13 アルパイン株式会社 ナビゲーション装置
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
CA2539253A1 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouveaux derives de glp-1
CN1657540A (zh) * 2004-02-18 2005-08-24 中国人民解放军军事医学科学院基础医学研究所 人甲状旁腺素（1－34）的聚乙二醇化衍生物，含有它们的药物组合物及用途
JP4950022B2 (ja) 2004-03-23 2012-06-13 コンプレックス バイオシステムズ ゲーエムベーハー 自壊性リンカーを有する高分子プロドラッグ
RU2006143544A (ru) 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
CN1597697A (zh) * 2004-07-19 2005-03-23 中国药科大学 一种人的甲状旁腺素1－34肽相关肽－Pro－Pro－[Arg11]]hPTH(1－34)－Pro－Pro
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US20060045912A1 (en) 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN1298386C (zh) 2005-08-31 2007-02-07 上海交通大学 甲状旁腺激素缓释微球的制备方法
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
AU2007225056A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
NO325064B1 (no) * 2006-07-06 2008-01-28 Tandberg Telecom As Kommunikasjonsklient
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
ATE469173T1 (de) 2006-10-13 2010-06-15 Lilly Co Eli Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung
US8101729B2 (en) 2007-03-19 2012-01-24 Henry Joseph Niemczyk Pegylated amino acid derivatives and the process to synthesize the same
ES2675174T3 (es) 2007-04-09 2018-07-09 The Board Of Trustees Of The University Of Arkansas Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea
HRP20110368T1 (hr) 2007-06-21 2011-06-30 Technische Universitt Mnchen Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
EP2175878A4 (fr) 2007-07-11 2014-12-03 Belrose Pharma Inc Système d'administration de médicament polymérique contenant un groupement aromatique multi-substitué
EP2052736A1 (fr) 2007-10-26 2009-04-29 Nycomed Danmark ApS Formulations d'hormones parathyroïdiennes et leurs utilisations
CN101980725B (zh) 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
DK2279007T3 (en) 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
EP2288261A4 (fr) 2008-05-23 2013-09-25 Enzon Pharmaceuticals Inc Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d oligonucléotides
WO2009156481A1 (fr) 2008-06-25 2009-12-30 Ascendis Pharma As Bnp pégylé
US20110195900A1 (en) 2008-08-19 2011-08-11 Ferring B.V. Peptidic pth receptor agonists
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
EP2459225A1 (fr) 2009-07-31 2012-06-06 Ascendis Pharma A/S Promédicaments de pramipexole liés à un support
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
ES2833035T3 (es) 2009-07-31 2021-06-14 Ascendis Pharma As Hidrogeles biodegradables insolubles en agua a base de polietilenglicol
WO2011012723A1 (fr) 2009-07-31 2011-02-03 Ascendis Pharma As Compositions injectables à libération prolongée contenant un promédicament du pramipexole
AU2010277559B2 (en) 2009-07-31 2016-08-11 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
PT2459171T (pt) 2009-07-31 2017-08-16 Sanofi Aventis Deutschland Composição de insulina de atuação longa
EP2485767A1 (fr) 2009-10-06 2012-08-15 Ascendis Pharma A/S Promédicaments à base de palipéridone liée à un support
DK2512450T3 (en) * 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US20110229580A1 (en) 2010-03-22 2011-09-22 Indian Institute of Technology Bombay, School of Biosciences and Bioengineering Compositions and methods for nano-in-micro particles
EP3372617B1 (fr) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
DK2566334T3 (en) 2010-05-05 2018-07-23 Prolynx Llc MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
JP5941040B2 (ja) 2010-05-13 2016-06-29 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン類似体およびその使用
AU2011254564B2 (en) 2010-05-21 2014-03-27 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
US8865220B2 (en) 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
US8989456B2 (en) 2010-06-30 2015-03-24 Nec Solution Innovators, Ltd. Attribute determining method, attribute determining apparatus, program, recording medium, and attribute determining system
US20120040320A1 (en) 2010-08-13 2012-02-16 Nadeau Daniel A Injection Simulation Device and Methods Thereof
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
JP6092867B2 (ja) 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
MX2014001496A (es) 2011-08-12 2014-04-30 Ascendis Pharma As Composicion de liberacion sostenida de prostaciclina.
US20140249093A1 (en) 2011-08-12 2014-09-04 Ascendis Pharma A/S Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages
WO2013024048A1 (fr) 2011-08-12 2013-02-21 Ascendis Pharma A/S Promédicaments liés à des excipients polymériques hyperbranchés
WO2013036857A1 (fr) 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
MY171920A (en) 2011-10-12 2019-11-07 Ascendis Pharma Ophthalmology Div A/S Prevention and treatment of ocular conditions
US8883862B2 (en) 2012-01-12 2014-11-11 Kaohsiung Medical University Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel
BR112014017424A8 (pt) 2012-01-20 2017-07-04 Lupin Ltd formulação farmacêutica aquosa estabilizada e método para tratar osteoporose
EP2841109A1 (fr) 2012-04-25 2015-03-04 Ascendis Pharma A/S Promédicaments de médicaments comprenant des groupes hydroxyle
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
US9718868B2 (en) * 2012-08-28 2017-08-01 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
SG11201501914XA (en) 2012-10-11 2015-05-28 Ascendis Pharma Ophthalmology Division As Vegf neutralizing prodrugs for the treatment of ocular conditions
US9855340B2 (en) 2012-10-11 2018-01-02 Ascendis Pharma A/S Hydrogel prodrugs
EP2906245B1 (fr) * 2012-10-11 2021-01-13 Ascendis Pharma A/S Diagnostic, prévention et traitement de maladies articulaires
CN104955472A (zh) 2012-10-17 2015-09-30 诺和诺德保健股份有限公司 用于生长激素递送的脂肪酸酰化的氨基酸
AU2013353985B2 (en) 2012-12-07 2017-07-13 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
EP2988783A1 (fr) 2013-04-22 2016-03-02 Ascendis Pharma A/S Promédicaments liés à un hydrogel libérant des médicaments modifiés
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
US10040850B2 (en) 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag
EP2868326A1 (fr) 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptides inhibiteurs de l'interaction TEAD/YAP-TAZ
AU2015299055C1 (en) 2014-08-06 2021-05-06 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
MY199991A (en) 2015-01-09 2023-12-02 Ascendis Pharma Growth Disorders As Cnp prodrugs
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
SMT202400423T1 (it) * 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Profarmaci di pth
HUE070273T2 (hu) * 2016-09-29 2025-05-28 Ascendis Pharma Bone Diseases As Szabályozott hatóanyag-leadású PTH vegyületek
HUE063235T2 (hu) 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
SMT202300124T1 (it) * 2016-09-29 2023-05-12 Ascendis Pharma Bone Diseases As Composti pth con bassi rapporti picco/valle
NZ751746A (en) * 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
SMT202500272T1 (it) 2018-05-18 2025-09-12 Ascendis Pharma Bone Diseases As Dose iniziale di coniugati di pth
WO2020165087A1 (fr) * 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Formulations pharmaceutiques liquides de conjugués pth
EP4090357A1 (fr) 2020-01-13 2022-11-23 Ascendis Pharma Bone Diseases A/S Traitement de l'hypoparathyroïdisme

Also Published As

Publication number Publication date
NZ785623A (en) 2024-10-25
KR102524255B1 (ko) 2023-04-20
AU2017227962A1 (en) 2018-08-09
CN115025239A (zh) 2022-09-09
FI3423103T3 (fi) 2024-11-20
DK3423103T3 (da) 2024-09-30
AU2023285850A1 (en) 2024-01-18
AU2020286303C1 (en) 2023-03-02
US20240123038A1 (en) 2024-04-18
HUS2500009I1 (hu) 2025-02-28
AU2020286303A1 (en) 2021-02-04
JP2019513127A (ja) 2019-05-23
KR102786270B1 (ko) 2025-03-24
MY208384A (en) 2025-05-05
ZA201805705B (en) 2019-06-26
LT3423103T (lt) 2024-10-25
FIC20250008I1 (fi) 2025-02-03
LTPA2025506I1 (fr) 2025-02-25
IL301616B2 (en) 2025-05-01
CN109069659A (zh) 2018-12-21
IL301616B1 (en) 2025-01-01
EP3423103B1 (fr) 2024-09-11
AU2022256158A1 (en) 2022-12-08
BR112018017091A2 (pt) 2019-01-02
US20220008516A1 (en) 2022-01-13
AU2022256158B2 (en) 2023-09-28
KR20250044469A (ko) 2025-03-31
PL3423103T3 (pl) 2025-02-10
SI3423103T1 (sl) 2024-12-31
MY196308A (en) 2023-03-24
CA3015585A1 (fr) 2017-09-08
JP7059195B2 (ja) 2022-04-25
US20250268988A1 (en) 2025-08-28
EP4470613A2 (fr) 2024-12-04
SMT202400423T1 (it) 2024-11-15
CA3015585C (fr) 2025-09-23
IL317744A (en) 2025-02-01
KR20180118197A (ko) 2018-10-30
EP3423103A1 (fr) 2019-01-09
KR20230015517A (ko) 2023-01-31
FR24C1045I1 (fr) 2025-01-10
HRP20241591T1 (hr) 2025-02-28
RU2018134135A (ru) 2020-04-01
IL260756B2 (en) 2023-09-01
IL260756B1 (en) 2023-05-01
WO2017148883A1 (fr) 2017-09-08
AU2023285850B2 (en) 2025-09-18
ES2993932T3 (en) 2025-01-14
AU2017227962B2 (en) 2020-11-12
FR24C1045I2 (fr) 2025-10-10
JP7619973B2 (ja) 2025-01-22
NZ745318A (en) 2023-01-27
JP2022068210A (ja) 2022-05-09
AU2025279737A1 (en) 2026-01-15
US11793861B2 (en) 2023-10-24
HUE069445T2 (hu) 2025-03-28
NO2025005I1 (no) 2025-01-14
JP2025000652A (ja) 2025-01-07
NL301298I2 (nl) 2024-12-11
US20230121525A1 (en) 2023-04-20
RS66250B1 (sr) 2024-12-31
MX2018009938A (es) 2019-03-14
RU2747316C2 (ru) 2021-05-04
AU2022256158A9 (en) 2023-09-28
MX2022015755A (es) 2023-01-19
SG11201806092TA (en) 2018-08-30
IL260756A (fr) 2018-09-20
RU2018134135A3 (fr) 2020-04-01
CA3249706A1 (en) 2025-10-31
US20200276276A1 (en) 2020-09-03
US12214020B2 (en) 2025-02-04
AU2020286303B2 (en) 2022-07-21
KR102331820B1 (ko) 2021-11-29
CN115025239B (zh) 2025-03-21
IL301616A (en) 2023-05-01
CN109069659B (zh) 2022-04-19
EP4470613A3 (fr) 2025-03-12
US20200360487A1 (en) 2020-11-19
MA45809B1 (fr) 2024-12-31
US20200376089A1 (en) 2020-12-03
KR20210147085A (ko) 2021-12-06
MA45809A (fr) 2019-01-09
AU2017227962C1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
FR24C1045I2 (fr) Promédicaments de pth
EP3482279A4 (fr) Élément d'intérieur de véhicule
CL2015003114S1 (es) Automovil
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
PT3157915T (pt) Compostos de dihidroisoquinolinona substituídos
UA32547S (uk) Автомобіль
CL2015002393S1 (es) Automóvil
CL2015001896S1 (es) Vehiculo
CL2015003626S1 (es) Automóvil
PL3518982T3 (pl) Związki pth o kontrolowanym uwalnianiu
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2015001956S1 (es) Automovil
EP3435660A4 (fr) Visiocasque
CL2015003382S1 (es) Automóvil
MA43957A (fr) Biomarqueurs de copanlisib
SMT202200173T1 (it) Composti
CL2015003155S1 (es) Automóvil
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
EP3309163A4 (fr) Dérivé de dihydropyrrolopyrazole substitué
CL2015002005S1 (es) Automovil
CL2015001801S1 (es) Automovil
CL2015002006S1 (es) Automovil
CL2014002313S1 (es) Aparato de iluminacion
EP3523659C0 (fr) Procédé multi-protéase
EP3454107A4 (fr) Visiocasque